New York City, NY -- (SBWIRE) -- 10/15/2013 -- StockMarketIntel.com issues a special report on the following stocks: AMR Corporation (OTCMKTS:AAMRQ), Bank of America Corp (NYSE:BAC), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Coronado Biosciences Inc (NASDAQ:CNDO)
AMR Corporation (OTCMKTS:AAMRQ) gained 2.20%, trading on 3.94 million shares, to end the trade at $5.12. The stock changed hands in a range of $4.83 to $5.13, bringing its market capitalization to about $1.72 billion. If we look at its trading history of the past 52 weeks, the share price suffered a low of $0.36 and was moved to the maximum level of $7.15. AMR Corporation (AMR) operates in the airline industry. The Company’s principal subsidiary is American Airlines, Inc. (American). As of December 31, 2011, American provided scheduled jet service to approximately 160 destinations throughout North America, the Caribbean, Latin America, Europe and Asia. AMR Eagle Holding Corporation (AMR Eagle), a wholly owned subsidiary of AMR, owns two regional airlines, which do business as American Eagle - American Eagle Airlines, Inc. and Executive Airlines, Inc. (collectively, the American Eagle carriers). American also contracts with an independently owned regional airline, which does business as AmericanConnection (the AmericanConnection carrier).
What was the Moving Force behind AAMRQ on Bullish Run? Read This Research Report
Bank of America Corp (NYSE:BAC) added 1.13%, to complete the trading session at $14.35, with a total volume of 78.37 million shares. The stock, on average, trades on a volume of 84.47 million shares. It floated in a range of $14.05 to $14.39 during the last trading session, with a beta value of 2.64. Its market capitalization now moved to about $154.16 billion. In the past 52 weeks, the share price has not declined below $8.92 and above $15.03. Bank of America Corporation (Bank of America) is a bank holding company, and a financial holding company. Bank of America is a financial institution, serving individual consumers, small and middle market businesses, corporations and Governments with a range of banking, investing, asset management and other financial and risk management products and services.
For How Long BAC will fight for Profitability? Read This Trend Analysis report
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) recorded a fall of -1.41% and was in a range of $3.98-$4.54 before closing at $4.20. The stock completed the day with a total volume of 34.09 million shares, versus an average volume of 9.36 million shares. The share price hit its 52-week low of $3.98 and $25.40 was the best price. ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. As of January 11, 2013, additional clinical trials of Iclusig in other cancers were ongoing.
Why Should Investors Buy ARIA After the Recent Fall? Just Go Here and Find Out
Coronado Biosciences Inc (NASDAQ:CNDO) declined -66.90% yesterday, bringing its market capitalization around $64.83 million. The share price, after opening at $1.79, made a high of $2.16 and hovered above $1.73 to end the day at $1.91. The total number of shares that changed hands during the session was 26.24 million shares, as compared to average trading volume of 552,881 million shares. Coronado Biosciences, Inc. is a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer. The Company’s two principal pharmaceutical product candidates in clinical development include Trichuris suis ova or CNDO-201 (TSO) a biologic comprising of the microscopic eggs of the porcine whipworm, for the treatment of autoimmune diseases, such as Crohn’s disease (Crohn’s), ulcerative colitis (UC) and multiple sclerosis (MS), and CNDO-109, a compound that activates natural killer (NK) cells of the immune system to seek and destroy cancer cells, for the treatment of acute myeloid leukemia (AML). In January 2011, the Company acquired the OvaMed GmbH License.
Will CNDO Get Buyers Even After The Recent Rally? Find Out Here
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)